Physician profile
Bernard D Gojer
NPI 1245232768
$8,042.25
in general payments reported to CMS, 2019-2025
37 companies · $572 in 2025
The $572 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,492 · 2020: $977 · 2021: $1,934 · 2022: $928 · 2023: $1,174 · 2024: $965 · 2025: $572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,711.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,710.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,180.02 | 2019-2025 | Leqvio |
| Pfizer INC. | $1,170.65 | 2019-2025 | |
| Boston Scientific Corporation | $654.74 | 2019-2024 | Eluvia, Opticross, Avvigo Guidance System |
| Amgen INC. | $525.44 | 2019-2023 | Repatha |
| Abiomed | $517.63 | 2020-2025 | Impella |
| Janssen Pharmaceuticals, INC | $486.87 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $383.46 | 2021-2025 | Verquvo |
| Shockwave Medical, INC | $380.93 | 2023-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $367.51 | 2020-2024 | Jardiance |
| Amarin Pharma, INC. | $323.72 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $240.29 | 2019-2025 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $237.56 | 2019-2024 | Lifevest |
| Alnylam Pharmaceuticals INC. | $192.92 | 2021-2025 | Amvuttra |
| Abbott Laboratories | $161.56 | 2019-2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Sanofi-Aventis U.S. LLC | $124.26 | 2019-2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $121.57 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $116.37 | 2019-2024 | Farxiga |
| Actelion Pharmaceuticals US, INC. | $74.19 | 2021-2025 | Uptravi, Opsumit |
| Celonova Biosciences, INC. | $66.69 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $62.88 | 2021-2023 | |
| Baxter Healthcare | $60.80 | 2023-2024 | Hillrom - Cardiac Ambulatory Monitor |
| Esperion Therapeutics, INC. | $57.42 | 2021-2023 | Nexletol |
| Heartflow, INC. | $56.74 | 2024-2025 | |
| Irhythm Technologies, INC. | $53.77 | 2021-2022 | |
| Philips North America LLC | $44.89 | 2022-2023 | |
| Inari Medical, INC. | $44.68 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Novo Nordisk INC | $44.63 | 2024 | Rybelsus, Ozempic, Wegovy |
| Kowa Pharmaceuticals America, INC. | $43.20 | 2021-2022 | |
| Gilead Sciences, INC. | $41.98 | 2019 | |
| Silk Road Medical, INC. | $40.99 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Elutia, INC. | $35.55 | 2021 | |
| Bardy Diagnostics, INC. | $30.00 | 2022 | |
| Cardiva Medical, INC. | $28.64 | 2025 | Cardiva Vascade 6/7f Vcs |
| Lexicon Pharmaceuticals, INC. | $19.16 | 2024 | |
| Angiodynamics, INC. | $19.12 | 2021 | |
| Bridgebio Pharma, INC. | $16.32 | 2025 | Attruby |
| Regeneron Healthcare Solutions, INC. | $15.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernard Gojer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.